Guidance on the use of biological agents in the treatment of oral mucosal disease

British Journal of Dermatology

Volumn 162, Issue 6, 2010, Pages 1410-1411

  O'Neill, I ^a  

^a Centre d'Affaires Poincare   (France)

Author keywords

Aphthous ulceration; Biologics; Off label use; Stomatitis; TNF antagonists

Indexed keywords

ADALIMUMAB; ALEFACEPT; ETANERCEPT; INFLIXIMAB; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

DISEASE SEVERITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; MORBIDITY; OFF LABEL DRUG USE; ORAL MUCOSAL DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE;

BIOLOGICAL PRODUCTS; HUMANS; IMMUNOMODULATION; MOUTH DISEASES; MOUTH MUCOSA; OFF-LABEL USE; PRACTICE GUIDELINES AS TOPIC;

EID: 77952713259     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.09704.x     Document Type: Letter

References (9)

1. Smith CH, Anstey AV, Barker JN et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009 161 : 987 1019.
2. Menter A, Gottlieb A, Feldman SR et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008 58 : 826 850. (Pubitemid 351509656)
3. Nast A, Kopp I, Augustin M et al. German evidence-based guidelines for the treatment of psoriasis vulgaris (short version). Arch Dermatol Res 2007 299 : 111 138. (Pubitemid 46835379)
4. Furst DE, Keystone EC, Fleischmann R et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis 2010 69 : i2 29.
5. Wiedmann MW, Mössner J, Baerwald C, Pierer M. TNF alpha inhibition as treatment modality for certain rheumatologic and gastrointestinal diseases. Endocr Metab Immune Disord Drug Targets 2009 9 : 295 314.
6. Graves JE, Nunley K, Heffernan MP. Off-label uses of biologics in dermatology: Rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2). J Am Acad Dermatol 2007 56 : e55 79.
7. O'Neill ID. Off-label use of biologicals in the management of inflammatory oral mucosal disease. J Oral Pathol Med 2008 37 : 575 581.
8. Melikoglu M, Fresko I, Mat C et al. Short-term trial of etanercept in Behçet's disease: A double blind, placebo controlled study. J Rheumatol 2005 32 : 98 105.
9. Hatemi G, Silman A, Bang D et al. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis 2008 67 : 1656 1662.